Efmarodocokin alfa

依玛白介素 22-α

Report date: 2026/02/12 20:00:14

Base Information

Drug NameEfmarodocokin alfa
Drug Alias NameRG-7880RO-7021610UTTR-1147A
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion protein > Fc fusion protein
Mechanisms of ActionInterleukin-22 receptor modulators
TargetsInterleukin-22 receptor
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)Graft vs Host DiseaseDiabetic Foot +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBulgariaUnited StatesUkraine +[20] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesGenentech Inc
China Registration ClassN/A

Develop Information

Active CompaniesGenentech Inc
Inactive CompaniesN/A
Active IndicationsGraft vs Host DiseaseColitis, Ulcerative
Inactive IndicationsCoronavirus Disease 2019 (COVID-19)Diabetic FootCrohn Disease

Other Information

ATC CodeN/A
Related LinksN/A